Patient Navigator Intervention for Diabetic Retinopathy (SEEN)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This is a pilot study of a patient navigator intervention for people living with diabetes and at high risk of diabetic blindness. The investigators are assessing the feasibility and acceptability of the intervention in preparation for a clinical trial.
Full description
Evidence-based treatment for Diabetic retinopathy (DR) established 30 years ago decreases the likelihood of blindness by 50%. Outcomes are even better now with emerging therapies and technology. Diabetes remains the leading cause of new cases of legal blindness. This study is significant because it investigates the gap between published guidelines and the population that continues to go blind despite well-established recommendations for screening. Our current model of screening for DR screens much of the population appropriately. There is an opportunity to improve DR screening by timely identification of persons at risk for preventable blindness. DR disproportionately impacts Non-Hispanic Blacks, Latinos, Native Americans, and lower socioeconomic communities. Racial and ethnic minorities are less likely to be screened for DR, have a higher prevalence of disease, and more severe disease. There is not a clear path toward decreasing these disparities beyond these data. This study addresses barriers to the implementation of evidenced-based treatment protocols by identifying modifiable patient and population-level challenges and building an intervention informed by community members and national data. It is a direct response to the "population health imperative" described by the National Academies of Science, Engineering, and Medicine. Our study answers the National Eye Institute's Strategic Plan request to evaluate disparities by identifying barriers that prevent optimal treatment. It is aligned with the NEI's mission to support research and training with respect to the preservation of sight. The National Institute on Minority Health and Health Disparities Research Framework provides the conceptual foundation for our work. Our proposal identifies facets of the biologic, built, and sociocultural environments of the national population with undiagnosed DR. The national analysis informs a local individual-level intervention that addresses determinants associated with DR screening. The scientific premise of this study is the forty percent of persons with diabetes not screened despite established sight-saving treatment, the known disparities in screening for DR, and the increased prevalence of sight-threatening DR in Black, Latino, Native, and lower income Americans.
Primary Objective The primary objective of this study is to design and pilot a patient navigator program to increase screening for DR in a high-risk population.
Secondary Objective To determine the feasibility and accessibility of a patient navigation program for persons at high-risk for DR.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Adults aged 18 and over
- Diagnosis of diabetes and record of diagnosis in YNHHS EPIC
- English-speaking
- No documented eye examination within 1 year of study enrollment
- High risk for diabetic retinopathy based on risk calculator evaluation
Exclusion criteria
- Documented eye exam in the past year
- Not high risk for diabetic retinopathy
- Diabetes diagnosis not recorded in EPIC
Trial design
Primary purpose
Allocation
Interventional model
Masking
35 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Kristen Nwanyanwu, MD, MHS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal